Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2015

Katayama Ryohei, Lovly Christine M, Shaw Alice T

Abstract excerpt

The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase was initially discovered as a component of the fusion protein nucleophosmin (NPM)-ALK in anaplastic large-cell lymphoma (ALCL). Genomic alterations in ALK, including rearrangements, point mutations, and genomic amplification, have now been identified in several malignancies, including lymphoma, non-small cell lung cancer (NSCLC), neuroblastoma,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Molecular Targeted Therapy

Share to Oncogene Proteins, Fusion

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 25979929
DOI: 10.1158/1078-0432.CCR-14-2791
PMCID: PMC4435823

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.PMID 25979929Read ↗

Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment.Semantic proximity Read ↗

Unraveling the Potential of ALK-Targeted Therapies in NSCLC: Comprehensive Insights and Future DirectionsSemantic proximity Read ↗

Targeting Anaplastic Lymphoma Kinase in Lung CancerSemantic proximity Read ↗

Anaplastic lymphoma kinase: Role in cancer and therapy perspective.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.Semantic proximity Read ↗

ALK in lung cancer: past, present, and future.Semantic proximity Read ↗

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.Semantic proximity Read ↗

ALK alterations and inhibition in lung cancer.Semantic proximity Read ↗

Targeted therapy for lung cancer: Beyond EGFR and ALK.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.Semantic proximity Read ↗

Anaplastic lymphoma kinase in human cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.